1039例隐源性肝炎患者AMA-M2 抗体的筛查

doi:10.3969/j.issn.1672-5069.2012.03.021

Abstract

Abstract: Objective To investigate the presence of AMA-M₂ antibodies in 1039 patients with cryptogenic hepatitis. Methods M₂ antibodies were tested by ELISA. Results M₂ antibodies were detected in 81（7.9%）of the 1039 patients;Of the 81 cases,57 were female and 24 were male,and the mean age was 53.0 ± 14.8 year old,and 78 patients were diagnosed as PBC;The most common symptoms were fatigue（74.4%,58/78）,jaundice（61.5%,48/78）and skin itching（37.2%,29/78）;Besides,39（50.0%） patients were with ANA positive,and 14（18.0%） with anti-SSA/Ro positive. Conclusion On the diagnosis of the disease,the detection of serum antimitochondrial autoantibodies（AMA） is an important indicator. The detection of AMA-M₂ is important for early diagnosis of patients with PBC.

Key words: Cryptogenic hepatitis, Primary biliary cirrhosis, Anti-mitochondria M2 antibodies

Zhang Wei, Wang Lei, Wang Yi, et al.. Measurement of anti-mitochondria M₂ antibodies in 1039 patients with cryptogenic hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(3): 238-240.

References

[1] Lleo A,Battezzati PM,Selmi C,et al. Is autoimmunity a matter of sex?. Autoimmun Rev,2008,7:626-630.
[2] Roblin X,Bonaz B.Primary biliary cirrhosos. N Engl J Med,2005;353:2719-2720.
[3] Prince MI,Chetwynd A,Craig WL,et al. Asymptomatic primary biliary cirrhosis:clinical features,prognosis,and symptom progression in a large population based cohort. Gut,2004,53:865-870.
[4] Selmi C,Bowlus C,Gershwin ME,et al. Primary biliary cirrhosis. Lancet,2011,377:1600-1609.
[5] Invernizzi P. Update on primary biliary cirrhosis. Digest Liver Dis,2010,42:401-408.
[7] Muratori P,Granito A,Pappas G,et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol,2009,104（6）:1420-1425.
[8] 蒋天舒,周晔,邓安梅,等. 原发性胆汁性肝硬化研究进展. 中国实验诊断学,2006,10（12）：1539-1541.
[9] Gershwin ME,Mackay IR. The causes of primary biliary cirrhosis:convenient and inconvenient truths. Hepatology,2008,47:737-745.
[10] Shimoda S,Miyakawa H,Nakamura M,et al. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun,2008,31:110-115.
[11] Shimoda S,Harada K,Niiro H,et al. Biliary epithelial cells and primary biliary cirrhosis:the role of liver-infiltrating mononuclear cells. Hepatology,2008,47:958-965.
[12] Murator I,Granito A,Ferri S,et al.Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis .Autoimmunity,2009,42:224-227.
[13] Agmon-levin N,Shapira Y,Selmi C,et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun,2010,34:55-58.
[14] Invernizzi P,Lleo A,Podda M. Interpreting serological tests in diagnosing autoimmune liver disease. Semin Liver Dis, 2007,27:161-172.
[15] Vleggaar FP,Van Buuren HR. No prognostic signif icance of antim-itochondrial antibody profile testing in primary biliary cirrhos-is. Hepatogastroenterology,2004,51（58）:937-940.
[16] Metcalf JV,Mitchison HC,Palmer JM,et al. Natural history of early primay biliary cirrhosis. Lancet,1996,348:1399-1402.
[17] Muratori P,Muratori L,Ferrari R,et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol,2003,98:431-437.
[18] Zhang W,Yang GX. Fine phenotypic and functional characterization of effector CD8（+） T cells in patients with primary biliary cirrhosis. Hepatology,2011,[Epub ahead of print]
[19] Hsu W,Zhang W,Tsuneyama K,et al. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha（-/-）mice.Hepatology,2009,49:133-140.
（校对：陈从新）

[1]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[2]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[3]	Liu Jinguo, Wang Baokui. Efficacy of Fufangbiejia Ruanganpian and ursodeoxycholic acid combination in the treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 340-343.
[4]	Qin Wei, Chen Yuping, Yang Zhao, et al. Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 237-240.
[5]	Chen Xiaojun, Song Yang. Changes of peripheral blood T lymphocyte subsets and efficacy of ursodesoxycholic acid and vitamin D combination in treatment of patients with primary biliary cholangitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 80-83.
[6]	Tao Mingling, Zhang Shibin, Wu Yanjing, et al.. Non-invasive predictors of esophageal varices in patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 439-442.
[7]	Liu Funa, Liu Jiangkui, Shen Yihui.. Efficacy of ursodeoxycholic acid and prednisolone combination in treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 443-446.
[8]	Guo Rui, Tan Jin.. A randomized controlled trial of ursodeoxycholic acid in treating patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 109-110.
[9]	Han Yongbin， Liu Xin，Wang Aifang， et al.. Primary biliary cirrhosis misdiagnosed as bone marrow hyperplasia syndrome: A case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 747-748.
[10]	Hao Jianhong,Hao Haiyan,Hu Yiling. Clinical features of primary biliary cirrhosis: An analysis of 94 cases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 352-353.
[11]	Zhou Xinren, Wang Fang, Yun Shenghao. Intrahepatic transplantation of umbilical cord blood stem cells in treatment of patients with decompensated primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 219-220.
[12]	Wang Gui， Wang Jiangbin.. Features of elderly patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 573-574.
[13]	Kong Xianglu，Guo Xiaoxia. Systemic review of Chinese herbal medicine combined with ursodeoxycholic acid in treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 379-382.
[14]	Li Pingying，Lu Lungen. Advances in pharmacotherapy of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 441-444.
[15]	Chen Jing, Jia Gui, Gao Zhengjun, et al.. Smoking and primary biliary cirrhosis:A case-control study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 164-167.

Measurement of anti-mitochondria M₂ antibodies in 1039 patients with cryptogenic hepatitis

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

Measurement of anti-mitochondria M2 antibodies in 1039 patients with cryptogenic hepatitis

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

Measurement of anti-mitochondria M₂ antibodies in 1039 patients with cryptogenic hepatitis